Teva (TEVA) Stock Forecast for 2025, 2026, 2027. Sell or Buy Prediction







Where to Rent Stable Turkish Datacenter Proxies?

July 1, 2025 Where to Rent Stable Turkish Datacenter Proxies?

In a digital landscape where online anonymity and efficiency are essential, datacenter proxies have become a fundamental tool for businesses, SEO specialists, and…
PayPal’s News Analysis—A Short and Medium-Term Price Forecast

June 24, 2025 PayPal’s News Analysis—A Short and Medium-Term Price Forecast

This analytical article cuts through the noise, offering a focused forecast for PYPL’s stock price movement in both the short (5 days) and…
Understanding Accounting and Bookkeeping Services for Business Success

June 10, 2025 Understanding Accounting and Bookkeeping Services for Business Success

Every successful business relies on accurate financial records. From managing cash flow to ensuring compliance with tax regulations, reliable accounting and bookkeeping services…
How much does a Turkish passport cost?

May 27, 2025 How much does a Turkish passport cost?

Turkish citizenship comes with numerous benefits. Once granted, a foreigner can enter 126 countries visa-free, enjoy high-quality healthcare and favorable tax regimes, and…
How Measurement and Mix Modeling Drive Better Business Decisions

May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions

In today’s data-driven business landscape, the ability to accurately measure and optimize marketing efforts has become a critical competitive advantage. As marketing evolves,…

Teva (TEVA) Stock Forecast for 2025, 2026, 2027. Sell or Buy?

Updated: July 9, 2025 (18:35)

Sector: Healthcare

The share price of Teva Pharmaceutical Industries Lim. (TEVA) (TEVA) now

Latest session on the 8th of July for
Teva Pharmaceutical Industries Lim. (TEVA) is negative
Trading Volume: 10796519
Open: 16.82 /  High: 16.88 /  Low: 16.55
Current value: $16.63
What analysts predict: $23.12
52-week High/Low: $22.8 / $12.46
50-Day Moving Average: $15.64 — support level today
200-Day Moving Average: $17.54 — resistance level today

News Impact Analyzer

Full report
This Week
Na Impact: Na News: Na
Previous Week
Na Impact: Na News: Na
Two Weeks Ago
Na Impact: Na News: Na
Three Weeks Ago
Bullish Impact: 5 News: 2 (1/1/0)

Analysts predictions

Full report
This Week
Bullish Opinions: 1 (1/0/0)
Previous Week
Neutral Opinions: Na
Two Weeks Ago
Bullish Opinions: 1 (1/0/0)
Three Weeks Ago
Neutral Opinions: Na

Analyzing the Most Important TEVA news

Generic Drugmakers Tread Carefully as Trump Pushes for U.S. Manufacturing

Jun 17, 2025
Trend: Neutral
Influence: 4
Teva’s cautious approach to Trump's domestic production push indicates stability rather than immediate action. While their existing U.S. footprint mitigates risks, uncertainty around tariffs limits significant impact on stock price. The market perceives this as neutral, with only minor influence on TEVA’s near-term valuation depending on upcoming policy decisions.

Teva Joins Forces with Fosun to Target Cancer Treatment Market with TEV-56278

Jun 16, 2025
Trend: Bullish
Influence: 8
The partnership positions Teva to expand its oncology portfolio globally while leveraging Fosun's strength in Asia-Pacific. The innovative anti-PD1-IL2 therapy has high market potential, driving premarket stock gains and investor confidence. This collaboration boosts prospects in cancer treatment, likely supporting TEVA's stock upward momentum in the near term.

Goldman Praises Teva: Bullish Outlook with $24 Target

Jun 06, 2025
Trend: Bullish
Influence: 8
Goldman Sachs’ Buy rating and $24 price target underline Teva’s growth potential, particularly from its branded drug portfolio. With a positive outlook and improving earnings, this endorsement could instill strong investor confidence, propelling the stock higher in the short to mid-term. The emphasis on innovation aligns well with current market expectations, driving the bullish sentiment.

Historical and forecast chart of Teva stock

The chart below shows the historical price of Teva stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Teva stock price can be found in the table below.

Long-term forecasts by years.

Teva Pharmaceutical Industries Lim. (TEVA) Analysts predictions review

Teva Pharmaceuticals shows potential for gradual recovery driven by a pivot to higher-margin biosimilars and specialty medicines, alongside operational efficiency and deleveraging efforts. These strategies enhance profitability and reduce risk. While the company's branded portfolio supports growth, challenges such as declining generics performance, legal risks from opioid litigation, and regulatory headwinds like the IRA may weigh on near-term results. Macroeconomic factors, including interest rates and currency fluctuations, also pose uncertainties. Successful execution of strategic initiatives will be key to sustaining investor confidence and improving long-term performance.

Teva Pharmaceuticals: Balancing Growth Opportunities Amid Regional Uncertainty

Trend: Bullish
May 23, 2025

Teva Pharmaceuticals' financial performance is heavily influenced by its ability to navigate regional risks, including political instability in key operational areas. The author's analysis asserts that while these factors present challenges, they are counterbalanced by the company's disciplined focus on operational efficiency and cost optimization, which are crucial for maintaining margins given the near-term economic pressures.

Growth Drivers and Headwinds

Another significant factor highlighted is Teva's commitment to diversifying its product pipeline, with a specific emphasis on biosimilars and specialty medicines. The successful execution of this strategy could provide a sustainable growth trajectory, as these segments offer higher margins compared to generics, positioning the company as a stronger player in the pharmaceutical market.

Further, Teva's ongoing deleveraging efforts were identified as a positive catalyst for the stock. By reducing debt levels, the company not only stabilizes its financial position but also improves its appeal to investors seeking reduced risk profiles. This could have a medium- to long-term positive impact on the stock price.

The author's perspective suggests that macroeconomic headwinds, particularly fluctuating interest rates and currency risks, remain an overhang on the stock. However, the company's effective risk management strategies and strong fundamentals mitigate the potential downside, solidifying its investment appeal despite these challenges.


Analyst: ALLKA Research
( Followers: 2250
Articles: 73 )

Teva Pharmaceuticals: Poised for Recovery and Investment Upside

Trend: Bullish
May 08, 2025

Teva Pharmaceuticals is undergoing a strategic transformation with several factors aligning to potentially strengthen its stock performance. The company has focused on diversifying its product portfolio, prioritizing higher-margin assets such as biosimilars and innovative treatments, which may significantly enhance its profitability. Analyst Array notes that this shift signals Teva’s commitment to counteract reliance on generic drugs, historically affected by intense pricing competition.

Key Drivers in Teva’s Turnaround Strategy

Teva has also made significant strides in operational efficiency, reducing its overall debt burden through disciplined expense management and asset optimization. This reduction not only improves its balance sheet strength but also positions the company to channel resources into future growth initiatives, which is a net positive for investor sentiment. Furthermore, its leadership appears determined to lead new initiatives that target core therapeutic areas like neurology and immunology, leveraging recent approvals and partnerships.

The company's legal challenges, particularly those involving opioid litigation uncertainties, remain a critical risk factor. According to Array, while potential settlements could weigh on short-term performance, their resolution may act as a long-term catalyst for improved investor confidence. Additionally, Array emphasizes that macroeconomic pressures such as fluctuating currency rates in key markets—although manageable—may influence near-term volatility. Overall, Teva seems positioned for a gradual but noteworthy recovery, assuming it successfully delivers on these key initiatives.


Analyst: Motti Sapir
( Followers: 557
Articles: 40 )

Teva: Navigating Strong Brand Growth Amid Generic Pressures and Policy Challenges

Trend: Neutral
Mar 06, 2025

Teva's ongoing momentum in its branded drug portfolio is a critical pillar of its growth strategy, with innovative therapies demonstrating robust demand. This development reflects positively on the company's ability to pivot towards high-margin specialty pharmaceuticals, fostering greater revenue resilience.

Balancing Growth Drivers and Risks in Teva's Outlook

Conversely, the continued decline in the generic drug segment underscores structural challenges, such as pricing pressure and competition, which weigh on the company's topline. These headwinds could erode profitability further if offset strategies are not effectively implemented.

Additionally, regulatory headwinds, particularly from the Inflation Reduction Act (IRA), present notable risks to long-term revenue. The potential impact of pricing reforms and government negotiations on Teva's product portfolio could dampen earnings, especially if the company remains overly reliant on affected segments.


Analyst: Stephen Ayers
( Followers: 8021
Articles: 832 )
Jan 19, 2025
Evaluating TEVA Pharmaceuticals: A Strategic Outlook Amid Immunology Market Growth
Trend: Neutral

TEVA Pharmaceuticals stands at a critical juncture within the immunology sector, benefiting from its diversified portfolio and a solid pipeline of drug development. Its position as a major player in the generic drugs market continues to provide the company with a cash flow safety net, enabling long-term investments in innovative treatments. However, intense competition in both generics and specialty drugs remains a notable pressure point for margins.

Growth Drivers and Challenges for TEVA

TEVA's recent focus on expanding its immunology offerings reflects a strategic pivot towards high-margin specialty drugs to counteract ongoing pricing struggles in the generics segment. This shift is likely to bolster revenue growth in the medium to long term if clinical trials and regulatory approvals proceed as planned. Additionally, the company's cost optimization measures, including facility consolidations and operating expense reductions, signal improved efficiency and profitability potential, which investors will closely monitor for tangible results in quarterly earnings.

On the downside, ongoing legal liabilities from opioid-related settlements present a recurring headwind for TEVA, adding uncertainty to future cash flow allocations. Moreover, foreign exchange volatility, given its significant international footprint, could further pressure earnings in the near term.

The author underscores that while TEVA exhibits significant long-term potential tied to its R&D efforts and market pivots, near-term risks warrant a cautious approach. Investors seeking exposure should weigh these opportunities against the risks of delayed regulatory approvals and macroeconomic challenges.

Analyst: ALLKA Research
( Followers: 1397
Articles: 49 )
Dec 27, 2024
Teva Pharmaceuticals: Evaluating Duvakitug's Role in Long-Term Growth
Trend: Neutral

Teva Pharmaceuticals' strategic focus on Duvakitug, a novel pharmaceutical product, highlights the company's efforts to revitalize its growth trajectory amidst a challenging competitive landscape. The drug is positioned as a potential breakthrough in its therapeutic category, potentially driving meaningful revenue growth if it gains strong market adoption and regulatory support. The author emphasizes the significance of this pipeline asset, underscoring its role in boosting confidence in Teva's innovation capabilities and long-term value.

Macroeconomic Environment and Operational Challenges

Broader macroeconomic conditions, including inflationary pressures and global supply chain disruptions, remain critical challenges for Teva. These factors could compress margins and slow operational recovery, especially as the company continues its debt-reduction efforts. The author also notes increased competition in the generics market, which may dampen price growth and offset revenue gains from innovative products like Duvakitug.

Cost management initiatives and restructuring measures are additional levers influencing Teva’s financial health. While these actions may enhance operational efficiency, they are not without execution risks that could delay the realization of cost savings. Furthermore, litigation risks stemming from opioid-related settlements could weigh on investor sentiment and potentially impact near-term stock performance.

Analyst: ALLKA Research
( Followers: 1314
Articles: 48 )
Dec 06, 2024
Can Teva Overcome Challenges to Regain Growth Momentum?
Trend: Neutral

TEVA's performance is strongly influenced by its ongoing restructuring efforts aimed at reducing debt and improving operational efficiency. These initiatives are crucial in restoring investor confidence, but their impact may take time to reflect materially on the stock price, limiting near-term upside potential.

Market conditions remain a key determinant of TEVA's trajectory, with generic drug pricing pressures and competitive dynamics continuing to challenge growth. The author's analysis highlights that overcoming these external headwinds will require more strategic product launches and a focus on innovative therapies.

Debt Levels and Pipeline Strategy

The company's high debt levels, though being reduced incrementally, still pose a significant risk to its financial flexibility. Addressing this concern while simultaneously investing in R&D is critical for TEVA’s ability to remain competitive in a rapidly evolving industry.

The pipeline remains a mixed bag, offering opportunities for upside through specialty drugs while underscoring the need to accelerate innovation. Success in this area will likely dictate the company’s medium- to long-term stock performance.

Analyst: Brendan O'Boyle
( Followers: 1656
Articles: 115 )
Dec 04, 2024
Teva: Stable Progress Amid Shrinking Valuation Upside
Trend: Neutral

Teva's operational fundamentals have shown significant improvement, particularly through its consistent focus on debt reduction and cost efficiencies. These actions signal strong financial discipline that enhances long-term sustainability, though they may have minimal immediate impact on driving the stock price higher in the near term.

Valuation and Growth Outlook

The author's analysis suggests that Teva's current valuation aligns with its improving fundamentals, reducing the likelihood of it being an undervalued opportunity. This equilibrium limits substantial upside potential unless new growth catalysts emerge or sector-wide sentiment improves.

Additionally, short-term headwinds, such as ongoing legal challenges and competition in generic drugs, remain key risks restraining price momentum. These elements weigh on investor confidence and have the potential to maintain pressure on the stock's near-term performance.

Analyst: Eugenio Catone
( Followers: 3307
Articles: 346 )
Oct 23, 2024
Teva Pharmaceuticals: A Strategic Buy Amid Debt Reduction and Growth Catalysts
Trend: Bullish

Teva Pharmaceuticals is capitalizing on its position as a leading generic drug manufacturer, which continues to drive stable revenue, particularly amidst rising demand for cost-effective healthcare solutions. The company’s dominance in generics insulates it against major competitive pressures, enhancing its allure as a long-term investment.

Leveraging Financial Discipline and Growth Prospects

Teva’s proactive debt reduction strategy has significantly strengthened its balance sheet, lowering financial risk and enhancing its capacity to reinvest in core operations. The removal of onerous financial obligations improves investor sentiment and positions the company for better forward-looking profitability.

Growth indicators, including new product launches and strategic market expansions, highlight management’s focus on innovation and operational efficiency. These developments provide tailwinds for revenue acceleration and improved market positioning in the near to medium term.

Finally, macroeconomic factors such as inflationary pressures and global healthcare trends are likely to favor Teva’s cost-effective drug offerings. As governments and insurers push for reduced healthcare expenditures, Teva is well-placed to benefit from elevated demand in key markets.

Analyst: Albert Anthony
( Followers: 1155
Articles: 278 )

Comprehensive Analysis of Teva (TEVA) Stock Market Performance


Our multifaceted analysis of Teva 's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:

  • When should I take profit in Teva stock?
  • When should I record a loss on Teva stock?
  • What are analysts' forecasts for Teva stock?
  • What is the future of Teva stock?

We forecast Teva stock performance using neural networks based on historical data on Teva stocks.

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generics, specialty drugs and biopharmaceutical products in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic agents in a variety of dosage forms, including tablets, capsules, injections, inhalers, liquids, ointments and creams. It also develops, manufactures and markets active pharmaceutical ingredients. In addition, the company provides specialized medicines for use in the central nervous system and respiratory indications. In addition, its products in the central nervous system and pain areas include Copaxone for the treatment of relapsing forms of MS; ADZHOVIY for the prophylactic treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. In addition, the company’s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair / Cinqaero and AirDuo RespiClick / ArmonAir RespiClick / AirDuo Digihaler for asthma and chronic obstructive pulmonary disease, as well as Bendeka products , Trisenox, Lonquex and Tevagrastim / Ratiograstim in the cancer market. She has cooperation agreements with Otsuka Pharmaceutical Co. LTD. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petah Tikva, Israel.

Teva Pharmaceutical Industries Lim. (TEVA) News influencing stock rates

As of now, Panda has combed through 2 news items directly related to TEVA from the last 30 days. Out of these, 1 clearly showcase a bullish trend, while 0 display bearish tendencies, and 1 events are neutral.

Based on an analysis of the most important news from the last 30 days affecting TEVA shares, it's clear that bullish sentiments are completely overshadowing bearish ones. The impact of positive news is more than five times as dominant as that of negative developments.

The news analyzed fell within the period from Jun 16, 2025, to Jun 17, 2025.

βeta
Jun 04, 2025

Teva Streamlines Debt with Strategic Tender Offers

Trend: Bullish
Influence: 7
Teva's proactive debt management signals financial discipline and stability, positively impacting investor sentiment. By optimizing its capital structure and extending debt maturities, the company reduces risk and positions itself for long-term growth. This financial maneuver enhances confidence and could support upward momentum in TEVA stock, making a bullish outcome plausible in the near term.
May 28, 2025

Teva's Strategic Growth: Truist Upgrades to Buy Ahead of Innovation Day

Trend: Bullish
Influence: 7
Truist's Buy recommendation and optimistic outlook for Teva's Innovation & Strategy Day signal confidence in the company's long-term growth. This positive sentiment, along with expectations for a 5-year strategy update, could drive investor interest and boost the stock price in the near term, particularly given the Strong Buy consensus from Wall Street.
May 20, 2025

Teva Upsizes Senior Notes Offering to $2.3B: A Strategic Financial Move

Trend: Neutral
Influence: 6
The upsizing of Teva's senior notes offering highlights strong investor confidence and provides the company with additional liquidity. However, this expands the firm's debt, which could limit upside potential for the stock in the short term. The announcement has a moderate impact, as it reflects careful financial management but does not directly alter earnings or operational performance.
May 12, 2025

Teva Gains Momentum with Upgraded Margin Clarity Through J.P. Morgan

Trend: Bullish
Influence: 8
J.P. Morgan's upgrade to Overweight highlights confidence in Teva's cost-cutting measures and margin improvements through 2027/28. Such positive recognition from a major financial institution can boost investor sentiment and drive upward pressure on the stock, marking a meaningful step in Teva's recovery strategy.
May 07, 2025

Teva's $2.5B Austedo Ambition Fuels Positive Growth Momentum

Trend: Bullish
Influence: 8
Teva's consistent revenue growth, coupled with its ambitious $2.5 billion sales goal for Austedo by 2027, signals strong operational execution and innovative strategic focus. These factors bolster investor confidence, making the news impactful and likely to positively influence TEVA's stock price in the near term. The 'Pivot to Growth' strategy reinforces a bullish sentiment.
May 07, 2025

Teva Stocks Climb Despite Q1 Revenue Miss Due to Forex Challenges

Trend: Neutral
Influence: 5
The post highlights forex-driven revenue underperformance but also notes that the stock still traded higher, suggesting market optimism. This balances the implications into a neutral trend. While impactful, the issue appears to be external (forex) rather than fundamental, hence moderate influence on stock price movement in the near term.
May 07, 2025

Teva Misses Full-Year Revenue Guidance Despite Q1 Gains

Trend: Bearish
Influence: 7
Teva's revision of its full-year revenue outlook below consensus, despite a slight rise in Q1 results, signals potential challenges ahead. Investors will likely respond negatively, as guidance cuts often suggest weaker future performance. This news creates moderate downward pressure on TEVA stock, emphasizing concerns about sustaining growth amidst divestitures and market headwinds.
May 06, 2025

Teva Pharmaceutical Q1 2025 Earnings: Expectations Set at $0.46 EPS Amid Revenue Growth

Trend: Neutral
Influence: 6
The slight decline in EPS (-4.2%) is offset by projected revenue growth (+4.5%), resulting in a mixed sentiment. Investors are likely to wait for actual results to reassess the financial direction of TEVA. While there is potential for moderate market reaction, the news carries mid-level influence given its balanced outlook and upcoming earnings report.
May 06, 2025

Viatris Loses EU Authorization for Generic Cancer Drug, Boosting Teva's Trisenox

Trend: Bullish
Influence: 8
The withdrawal of Viatris' generic variant in the EU eliminates a potential competitor for Teva's Trisenox, possibly strengthening its market position and revenue from this drug. This could positively influence investor sentiment, making the news significantly impactful for TEVA's stock performance in the short term.
May 05, 2025

Teva and Alvotech Secure FDA Approval for Biosimilar to Blockbuster Stelara

Trend: Bullish
Influence: 8
The FDA approval of Selarsdi as an interchangeable biosimilar to Johnson & Johnson's Stelara is a major win for Teva. It positions them in a high-growth biosimilar market, suggesting potential revenue growth. Given Stelara's significant market size, this approval may positively impact TEVA's stock price in the near term by boosting investor confidence.

Trending Themes in the Healthcare Sector

Teva daily forecast for a month

Date Target Pes. Opt. Vol., %
Jul 11 16.61 16.06 17.31 7.82
Jul 12 16.17 15.44 16.94 9.67
Jul 13 16.52 15.74 16.82 6.80
Jul 14 15.64 15.37 16.26 5.74
Jul 15 15.30 14.57 15.59 6.99
Jul 16 15.67 14.92 16.17 8.38
Jul 17 15.87 15.21 16.63 9.33
Jul 18 15.45 15.15 16.04 5.88
Jul 19 15.09 14.78 15.49 4.78
Jul 20 14.81 14.27 14.99 5.04
Jul 21 14.58 14.35 15.16 5.61
Jul 22 15.17 14.51 15.57 7.27
Jul 23 15.75 15.16 16.35 7.85
Jul 24 15.41 14.73 15.61 5.96
Jul 25 15.08 14.70 15.55 5.79
Jul 26 15.73 15.10 16.23 7.43
Jul 27 15.73 14.99 15.94 6.36
Jul 28 15.93 15.39 16.63 8.08
Jul 29 15.21 14.63 15.55 6.30
Jul 30 14.38 14.19 14.95 5.35
Jul 31 14.47 14.19 14.86 4.71
Aug 01 14.54 14.04 15.02 7.02
Aug 02 14.94 14.75 15.14 2.61
Aug 03 15.25 14.83 15.85 6.91
Aug 04 15.51 15.24 16.16 5.98
Aug 05 15.19 14.77 15.91 7.71
Aug 06 15.61 15.33 16.09 4.95
Aug 07 15.90 15.22 16.21 6.52
Aug 08 15.42 14.68 15.98 8.89
Aug 09 14.78 14.57 15.17 4.14

Teva Daily Price Targets


Teva Stock Forecast 07-11-2025.

Forecast target price for 07-11-2025: $16.61.
Negative dynamics for Teva shares will prevail with possible volatility of 7.251%.
Pessimistic target level: 16.06
Optimistic target level: 17.31

Teva Stock Forecast 07-12-2025.

Forecast target price for 07-12-2025: $16.17.
Negative dynamics for Teva shares will prevail with possible volatility of 8.821%.
Pessimistic target level: 15.44
Optimistic target level: 16.94

Teva Stock Forecast 07-13-2025.

Forecast target price for 07-13-2025: $16.52.
Positive dynamics for Teva shares will prevail with possible volatility of 6.365%.
Pessimistic target level: 15.74
Optimistic target level: 16.82

Teva Stock Forecast 07-14-2025.

Forecast target price for 07-14-2025: $15.64.
Negative dynamics for Teva shares will prevail with possible volatility of 5.425%.
Pessimistic target level: 15.37
Optimistic target level: 16.26

Teva Stock Forecast 07-15-2025.

Forecast target price for 07-15-2025: $15.30.
Negative dynamics for Teva shares will prevail with possible volatility of 6.534%.
Pessimistic target level: 14.57
Optimistic target level: 15.59

Teva Stock Forecast 07-16-2025.

Forecast target price for 07-16-2025: $15.67.
Positive dynamics for Teva shares will prevail with possible volatility of 7.734%.
Pessimistic target level: 14.92
Optimistic target level: 16.17

TEVA (TEVA) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jul. 19.19 17.81 20.11 11.45
Aug. 18.15 16.49 18.82 12.35
Sep. 16.78 14.98 17.46 14.15
Oct. 17.83 17.26 18.74 7.91
Nov. 17.95 16.77 19.30 13.10
Dec. 19.84 18.60 21.17 12.14

Teva forecast for this year


Teva Stock Prediction for Jul 2025

An uptrend is forecast for this month with an optimal target price of $19.1931. Pessimistic: $17.81. Optimistic: $20.11


Teva Stock Prediction for Aug 2025

An downtrend is forecast for this month with an optimal target price of $18.149. Pessimistic: $16.49. Optimistic: $18.82


Teva Stock Prediction for Sep 2025

An downtrend is forecast for this month with an optimal target price of $16.7842. Pessimistic: $14.98. Optimistic: $17.46


Teva Stock Prediction for Oct 2025

An uptrend is forecast for this month with an optimal target price of $17.8315. Pessimistic: $17.26. Optimistic: $18.74


Teva Stock Prediction for Nov 2025

An uptrend is forecast for this month with an optimal target price of $17.9457. Pessimistic: $16.77. Optimistic: $19.30


Teva Stock Prediction for Dec 2025

An uptrend is forecast for this month with an optimal target price of $19.8407. Pessimistic: $18.60. Optimistic: $21.17



Teva (TEVA) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 21.90 20.61 24.01 14.16
Feb 20.50 19.68 21.16 6.98
Mar 19.91 17.62 21.31 17.34
Apr 20.49 18.98 22.12 14.22
May 17.96 15.81 19.71 19.83
Jun 15.26 13.55 16.09 15.78
Jul 16.48 15.72 17.72 11.31
Aug 16.88 15.72 18.58 15.41
Sep 17.31 15.65 18.47 15.29
Oct 16.75 16.16 18.90 14.47
Nov 15.76 13.97 17.07 18.17
Dec 16.52 15.04 18.11 16.93

Teva (TEVA) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 18.24 16.14 19.17 15.83
Feb 15.35 13.63 16.77 18.74
Mar 13.24 11.63 13.89 16.31
Apr 13.36 11.70 14.77 20.84
May 11.63 11.17 12.58 11.24
Jun 12.34 11.67 12.85 9.22
Jul 13.64 12.18 14.91 18.30
Aug 13.75 12.26 15.25 19.62
Sep 15.89 15.33 16.52 7.23
Oct 15.15 13.35 17.09 21.84
Nov 16.29 15.74 17.75 11.31
Dec 15.19 14.00 16.31 14.16

Teva information and performance

Teva Address

5 BAZEL ST, P O B 3190, PETACH TIKVA, IL

Market Capitalization: 19 794 461 000 $

Market capitalization of the Teva Pharmaceutical Industries Lim. (TEVA) is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of TEVA shares in the company outstanding by the market price of one share.

EBITDA: 4 452 000 000 $

EBITDA of Teva is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: 1.293

Price/earnings to growth

DPS: None

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: None

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -1.15

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: 0.4
Quarterly Revenue Growth YOY: 0.019
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 6.64

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 2.136

Enterprise Value (EV) /Revenue

EV To EBITDA: 23.9

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 1146840000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Teva (TEVA) stock dividend

Teva last paid dividends on 11/27/2017. The next scheduled payment will be on 12/12/2017. The amount of dividends is $None per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.

Last Split Factor:

Last Split Date: 01/01/1970

Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.

For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.

FAQ (Frequently Asked Questions about Teva Stock)

Should I Buy Teva Shares in 2025 year?

The maximum forecasted share price for next year is $21.90, which is $5.27 higher than the current stock price. By investing in Teva shares today for a one-year period, you could achieve a profit of 31.71%. With an investment horizon of up to two years, the target share price is $18.24. resulting in a profit of 9.67% ($1.61 per share).

Does Teva pay dividends?

No, it does not

Which economic sector do Teva 's shares belong to?

Teva 's shares belong to the "Healthcare" sector of economic.

Which other securities belong to the same sector as Teva 's shares?

You can view all the stocks that are part of the same sector as Teva 's shares in the Healthcare section.


Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.